Abstract
Background Long-chain marine omega-3 fatty acids (eicosapentaenoic acid; EPA and docosahexaenoic acid; DHA) have anti-inflammatory effects. Dietary intake of EPA and DHA in pregnancy was associated with lower offspring risk of asthma in a randomized trial, and lower risk of type 1 diabetes in the offspring in retrospective observational studies.
Aim We aimed to investigate whether higher intakes of EPA and DHA during pregnancy is associated with a lower type 1 diabetes risk in children in two of the world’s largest birth cohorts.
Methods The Danish National Birth Cohort (DNBC) and the Norwegian Mother, Father and Child Cohort Study (MoBa) together include 153,843 mother-child pairs with prospectively collected data on EPA and DHA intake during pregnancy using validated food frequency questionnaires. Type 1 diabetes diagnosis in children (n=634) was ascertained from national diabetes registries.
Results There was no association between the sum of EPA and DHA intake during pregnancy and offspring risk of type 1 diabetes (hazard ratio per g/d of intake: 1.00 in both MoBa and DNBC, pooled 95% CI: 0.88-1.14). Adjustment for potential cofounders and robustness analyses gave very similar results.
Conclusion The hypothesis that a higher maternal omega-3 fatty acid intake during pregnancy reduce the risk of offspring type 1 diabetes was not supported.
Competing Interest Statement
JS serves as an adviser to Medtronic and Novo Nordisk. She owns shares in Novo Nordisk and has received fees for speaking on behalf of Medtronic, Sanofi Aventis, Rubin Medical and Novo Nordisk. None of the other authors had any conflict of interest to declare.
Funding Statement
The Danish National Birth Cohort is supported by the March of Dimes Birth Defects Foundation, the Danish Heart Association, the Danish National Research Foundation, the Danish Pharmaceutical Association, the Ministry of Health, the National Board of Health, and the Innovation Fund Denmark (grant 09-067124). The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research). PRN was supported by the European Research Council (AdG no. 293574), Stiftelsen Trond Mohn Foundation (Mohn Center of Diabetes Precision Medicine), the Research Council of Norway (FRIPRO grant no. 240413), the Western Norway Regional Health Authority (Strategic Fund Personalised Medicine for Children and Adults) and the Novo Nordisk Foundation (grant no. 54741). The sub-study on type 1 diabetes in DNBC was funded by the EFSD/JDRF/Lilly Programme. The sub-study on type 1 diabetes in MoBa was funded by Research Council of Norway (grant 2210909/F20) and the European Union Horizon 2020 research and innovation programme under grant agreement No 874864 HEDIMED.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all participants in both cohorts. The establishment of the cohort and data collection in MoBa were previously based on a license from the Norwegian Data Protection Agency and approval from The Regional Committee for Medical Research Ethics (S-95113/S-97045). They are now based on regulations related to the Norwegian Health Registry Act. The specific research question in the current sub-project was approved by the Regional Ethics Committee South-East C (2013/144/REK). The regional scientific ethics committee for the municipalities of Copenhagen and Frederiksberg approved all DNBC study protocols (27 August 2013: H-2-2013-108). All procedures were in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Computer codes for the statistical analyses and aggregated data are available from the corresponding authors upon request to the corresponding author. The consent given by the participants in the two cohorts does not open for storage of individual level data in repositories or journals. Access to individual level data sets from the MoBa database requires an application, approval from The Regional Committee for Medical and Health Research Ethics in Norway, and an agreement with MoBa and the endpoint registries, which can be obtained by applying at https://helsedata.no/en/ (for more information, see the MoBa website https://www.fhi.no/en/ch/studies/moba/, or email Mor.BarnData{at}fhi.no). Data from the Danish National Birth Cohort (DNBC) used in this study is managed by The DNBC Secretariat at Statens Serum Institut in Copenhagen, Denmark, and can be made available to researchers, provided approval from The DNBC organization, compliance with the EU General Data Protection Regulation (GDPR) and approval from the data owner (Statens Serum Institut). Researchers who wish to apply for access to data sets for replication purposes should apply through the DNBC Secretariat (see www.dnbc.dk). Access to data sets requires approval from the local Data Protection Agency (in a Danish context; "Fortegnelsen") at the researcher's institution and an agreement with the DNBC at Statens Serum Institut.
